Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastatic castration-resistant prostate cancer patient

Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastatic castration-resistant prostate cancer patient

Despite the development of new therapies in the last few years, metastatic prostate cancer (PCa) is still a lethal disease. Radium-223 (Ra-223) is approved for patients with advanced castration-resistant prostate cancer (CRPC) with bone metastases and no visceral disease. However, patients’ outcomes...

Full description

Bibliographic Details
Main Authors: Francesca Zacchi, Joan Carles, Macarena Gonzalez, Xavier Maldonado, Raquel Perez-Lopez, Maria Eugenia Semidey, Joaquin Mateo
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-03-01
Series:Frontiers in Oncology
Subjects:
Radium-223
bone response
bone metastases
metastatic castration-resistant prostate cancer
prognosis
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1331643/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1331643/full

Similar Items